Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 1, 2010, Pages 25-47

  Yan, Xiaoyu ^a   Mager, Donald E ^a   Krzyzanski, Wojciech ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Erythropoietin; Michaels Menten; Nonlinear pharmacokinetics; Target mediated drug disposition

Indexed keywords

CD4 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRX1; PHENYTOIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPUTER SIMULATION; DISSOCIATION CONSTANT; DRUG BINDING; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG TARGETING; MATHEMATICAL ANALYSIS; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; STEADY STATE; THEORETICAL MODEL;

ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NONLINEAR DYNAMICS; PHENYTOIN;

EID: 77949272760     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9142-8     Document Type: Article

References (31)

1. L Michaelis ML Menten 1913 Die Kinetik der Invertinwirkung Biochem Z 49 333 369 1:CAS:528:DyaC3sXhsFaqtw%3D%3D
2. Wagner J (1971) A new generalized nonlinear pharmacokinetic model and its implications. In: Wagner J (ed) Biopharmaceutics and relevant pharmacokinetics drug intelligence publications. Hamilton, IL, pp 302-317
3. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 507 532 10.1023/A:1014414520282 1:CAS:528:DC%2BD38XjsFSrtro%3D 11999290 (Pubitemid 34289541)
4. DE Mager 2006 Target-mediated drug disposition and dynamics Biochem Pharmacol 72 1 10 10.1016/j.bcp.2005.12.041 1:CAS:528:DC%2BD28Xltl2gt78%3D 16469301 (Pubitemid 43795346)
5. WJ Jusko 1989 Pharmacokinetics of capacity-limited systems J Clin Pharmacol 29 488 493 1:STN:280:DyaL1MzislGguw%3D%3D 2666450
6. RJ Bauer RL Dedrick ML White MJ Murray MR Garovoy 1999 Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis J Pharmacokinet Biopharm 27 397 420 10.1023/A:1020917122093 1:CAS:528:DC%2BD3cXjtFSntb8%3D 10826130
7. CM Ng A Joshi RL Dedrick MR Garovoy RJ Bauer 2005 Pharmacokinetic- pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis Pharm Res 22 1088 1100 10.1007/s11095-005-5642-4 1:CAS:528:DC%2BD2MXmt1yntbw%3D 16028009 (Pubitemid 41127066)
8. R Ramakrishnan WK Cheung MC Wacholtz N Minton WJ Jusko 2004 Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers J Clin Pharmacol 44 991 1002 10.1177/0091270004268411 1:CAS:528:DC%2BD2cXnvVyis74%3D 15317827 (Pubitemid 39096814)
9. GP Coffey JA Fox S Pippig S Palmieri B Reitz M Gonzales A Bakshi J Padilla-Eagar PJ Fielder 2005 Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice Drug Metab Dispos 33 623 629 10.1124/dmd.104.002584 1:CAS:528:DC%2BD2MXkt1Cmt78%3D 15673599 (Pubitemid 40593875)
10. GP Coffey E Stefanich S Palmieri R Eckert J Padilla-Eagar PJ Fielder S Pippig 2004 In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells J Pharmacol Exp Ther 310 896 904 10.1124/jpet.104.067611 1:CAS:528:DC%2BD2cXnt1eqt7o%3D 15190122 (Pubitemid 39108909)
11. CM Ng E Stefanich BS Anand PJ Fielder L Vaickus 2006 Pharmacokinetics/ pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers Pharm Res 23 95 103 10.1007/s11095-005-8814-3 1:CAS:528:DC%2BD28Xht1Cltr8%3D 16308668 (Pubitemid 43214665)
12. M Kato H Kamiyama A Okazaki K Kumaki Y Kato Y Sugiyama 1997 Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats J Pharmacol Exp Ther 283 520 527 1:CAS:528:DyaK2sXnsV2nu7k%3D 9353365
13. S Chapel P Veng-Pedersen RJ Hohl RL Schmidt EM McGuire JA Widness 2001 Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway J Pharmacol Exp Ther 298 820 824 1:CAS:528: DC%2BD3MXlsVKqt7o%3D 11454947
14. NH Al-Huniti JA Widness RL Schmidt P Veng-Pedersen 2004 Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia J Pharmacol Exp Ther 310 202 208 10.1124/jpet.104.066027 1:CAS:528:DC%2BD2cXlsVOjsL0%3D 14988424 (Pubitemid 38812712)
15. R Ramakrishnan WK Cheung F Farrell L Joffee WJ Jusko 2003 Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys J Pharmacol Exp Ther 306 324 331 10.1124/jpet.102.047191 1:CAS:528: DC%2BD3sXkvF2ksrs%3D 12676891 (Pubitemid 36734388)
16. S Woo W Krzyzanski WJ Jusko 2007 Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO) J Pharmacokinet Pharmacodyn 34 849 868 10.1007/s10928-007-9074-0 1:CAS:528:DC%2BD2sXhtlaqt7jE 17943422 (Pubitemid 350165278)
17. LK Roskos P Lum P Lockbaum G Schwab BB Yang 2006 Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects J Clin Pharmacol 46 747 757 10.1177/0091270006288731 1:CAS:528:DC%2BD28XntlWgsbo%3D 16809800 (Pubitemid 43882798)
18. DE Mager W Krzyzanski 2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition Pharm Res 22 1589 1596 10.1007/s11095-005-6650-0 1:CAS:528:DC%2BD2MXhtVent7vO 16180117 (Pubitemid 41355898)
19. L Gibiansky E Gibiansky T Kakkar P Ma 2008 Approximations of the target-mediated drug disposition model and identifiability of model parameters J Pharmacokinet Pharmacodyn 35 573 591 10.1007/s10928-008-9102-8 1:CAS:528:DC%2BD1cXhsFSmtLrK 19005743
20. OE Della Paschoa JW Mandema RA Voskuyl M Danhof 1998 Pharmacokinetic- pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats J Pharmacol Exp Ther 284 460 466 1:CAS:528: DyaK1cXhtFWksLk%3D 9454785
21. Burton ME, Shaw LM, Schentag JJ, Evans WE (2005) Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, Baltimore
22. A Marathe W Krzyzanski DE Mager 2009 Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model J Pharmacokinet Pharmacodyn 36 199 219 10.1007/s10928-009-9118-8 1:CAS:528:DC%2BD1MXnvVOgs74%3D 19434483
23. H Akaike 1974 A new look at the statistical model identification IEEE Trans Automat Contr 19 716 723 10.1109/TAC.1974.1100705
24. Gabrielsson J, Weiner D (2007) Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. Swedish Pharmaceutical Press, Stockholm, Sweden
25. AK Abraham W Krzyzanski DE Mager 2007 Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition AAPS J 9 E181 E189 10.1208/aapsj0902020 17614360
26. G Levy 1994 Pharmacologic target-mediated drug disposition Clin Pharmacol Ther 56 248 252 10.1038/clpt.1994.134 1:STN:280:DyaK2M%2FgvVGqsw%3D%3D 7924119
27. M Jarsch M Brandt M Lanzendorfer A Haselbeck 2008 Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay Pharmacology 81 63 69 10.1159/000109166 1:CAS:528:DC%2BD2sXhsVWjurbE 17901722 (Pubitemid 350124538)
28. P Veng-Pedersen KJ Freise RL Schmidt JA Widness 2008 Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin J Pharm Pharmacol 60 1321 1334 10.1211/jpp/60.10.0008 1:CAS:528:DC%2BD1cXhtlWiurvE 18812025
29. L Gibiansky E Gibiansky 2009 Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics Expert Opin Drug Metab Toxicol 5 803 812 10.1517/17425250902992901 1:CAS:528: DC%2BD1MXnsFamsb4%3D 19505189
30. Yan X, Mager DE, Krzyzanski W (2008) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. AAPS J 10(S2)
31. LA Peletier J Gabrielsson 2009 Dynamics of target-mediated drug disposition Eur J Pharm Sci 38 445 464 10.1016/j.ejps.2009.09.007 1:CAS:528:DC%2BD1MXhsVKgsL%2FN 19786099